Spero Therapeutics Q2 2024 Earnings Report $0.62 -0.08 (-11.61%) As of 04:00 PM Eastern Earnings HistoryForecast Spero Therapeutics EPS ResultsActual EPS-$0.33Consensus EPS -$0.34Beat/MissBeat by +$0.01One Year Ago EPS-$0.23Spero Therapeutics Revenue ResultsActual Revenue$10.20 millionExpected Revenue$9.80 millionBeat/MissBeat by +$400.00 thousandYoY Revenue GrowthN/ASpero Therapeutics Announcement DetailsQuarterQ2 2024Date8/5/2024TimeAfter Market ClosesConference Call ResourcesConference CallPress ReleaseSPRO Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by Remove Ads Spero Therapeutics Earnings HeadlinesTD Cowen Sticks to Their Hold Rating for Spero Therapeutics (SPRO)April 2 at 9:23 AM | markets.businessinsider.comWe're Keeping An Eye On Spero Therapeutics' (NASDAQ:SPRO) Cash Burn RateMarch 29, 2025 | finance.yahoo.comYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. Now… as new tariffs take effect, gold is breaking records again. You've hopefully already seen this in action… but gold is surpassing $3,000 per ounce for the first time EVER.April 3, 2025 | Premier Gold Co (Ad)Spero Therapeutics reports Q4 EPS (38c), consensus (31c)March 28, 2025 | markets.businessinsider.comSpero Therapeutics, Inc.: Spero Therapeutics Announces Fourth Quarter and Full Year 2024 Operating Results and Provides a Business UpdateMarch 28, 2025 | finanznachrichten.deSpero Therapeutics, Inc. (SPRO) Q4 2024 Earnings Call TranscriptMarch 27, 2025 | seekingalpha.comSee More Spero Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Spero Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Spero Therapeutics and other key companies, straight to your email. Email Address About Spero TherapeuticsSpero Therapeutics (NASDAQ:SPRO), a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.View Spero Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Intuitive Machines Gains After Earnings Beat, NASA Missions AheadCintas Delivers Earnings Beat, Signals More Growth AheadNike Stock Dips on Earnings: Analysts Weigh in on What’s NextAfter Massive Post Earnings Fall, Does Hope Remain for MongoDB?Semtech Rallies on Earnings Beat—Is There More Upside?These 3 Q1 Earnings Winners Will Go HigherWhat Is the Price-to-Earnings (P/E) Ratio? Upcoming Earnings Bank of New York Mellon (4/11/2025)BlackRock (4/11/2025)JPMorgan Chase & Co. (4/11/2025)Progressive (4/11/2025)Wells Fargo & Company (4/11/2025)Interactive Brokers Group (4/15/2025)Bank of America (4/15/2025)Citigroup (4/15/2025)Johnson & Johnson (4/15/2025)Morgan Stanley (4/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
